IMS audit levels point to overall increase of roughly 6 percent and 3 percent for oral anti-diabetic meds, both for new and total scrips. Here's the data:
AVANDIA: Total Rx down 16 percent, New Rx down 21 percent;
ACTOS: Total Rx up 20 percent, New Rx up 56 percent;
JANUVIA: Total Rx up 16 percent, New Rx up 26 percent;
BYETTA: Total Rx up 3 percent; New Rx up 5 percent.